aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-30 15:33Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is reminding investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against aTyr [4]. - Investors who purchased aTyr securities between January 16, 2025, and September 12, 2025, are encouraged to discuss their legal rights [1][4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids completely [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [7]. Group 3: Financial Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].